NCT07127510 · RECRUITING
Brain NAD in Alzheimer's Disease
This observational study is measuring NAD levels in the brains of people with and without Alzheimer's disease using a non-invasive MRI-based imaging technique called magnetic resonance spectroscopy. Participants get two brain scans eight months apart. The researchers want to know whether NAD, a molecule involved in cellular energy, is lower in Alzheimer's-affected brains. This is an observational study, meaning no drug or treatment is given — researchers are watching and measuring, not testing a therapy.
You may qualify if
- Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
- Age 65 to 80 included.
- People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
You're excluded if
- Under the age of 65 or over the age of 80.
- Advanced dementia such that the person would require sedation for undergoing an MRI scan.
- Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
- Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
- Having a history of seizures.
- Working at night.
- Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
- People with no AD: MoCA test result lower than 26.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-24